Schrodinger Inc. Stock News

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.76 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.38 per share a year ago.

NEW YORK--(BUSINESS WIRE)--Schrödinger will report its first quarter 2024 financial results on Wednesday, May 1, 2024, after the financial markets close.

What has been the top-performing stock so far of 2024? If you had said server installer Super Micro Computer (NASDAQ: SMCI ), that would be a great answer.

Small cap stocks like those discussed below tend to receive much less attention than their large cap competitors. Shares, which boast a market capitalization between $250 million and $2 billion, remai

Wall Street has correctly recognized that artificial intelligence (AI) is a game-changer. It enables individuals to use computers more easily than ever before to find the best answers to complex quest

While the top- and bottom-line numbers for Schrodinger, Inc. (SDGR) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metr

Schrodinger, Inc. (SDGR) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.39 per share a year ago.

Besides Wall Street's top -and-bottom-line estimates for Schrodinger, Inc. (SDGR), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared dur

The near- and medium-term outlooks for growth stocks have greatly improved in recent weeks. That's because it appears that the Street has, at long last, realized that relatively small increases in int

Artificial intelligence is being applied across the healthcare sector to improve delivery overall. AI stocks have the potential to impact stock sectors across the market positively, and healthcare is

Ahead of what could be significant uncertainties in the market, investors may be better served with cutting-edge biotech stocks. Fundamentally, the reasoning centers on relative insulation.

We're still in the initial stages of a massively disruptive artificial intelligence ( AI ) boom. Big Tech is investing billions of dollars into it.

Customers in the biopharma industry are cutting spending, creating a soft demand environment for Schrodinger's software and drug discovery services. Despite the recent share price spike, Schrodinger's

Better-than-expected labor productivity data for the U.S. economy reported on Nov. 2 was the reason behind the huge stock market rally that day. “Non-farm productivity, which measures hourly output

Schrödinger helps drugmakers discover high-quality leads for drug development. It has a star-studded cast of collaborators already, but it isn't growing much.